All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Tafasitamab receives positive CHMP opinion for R/R FL
On November 17, 2025, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion and recommendation for the approval of tafasitamab in combination with rituximab + lenalidomide for the treatment of adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥1 prior line of systemic therapy.1
This decision is based on results from the multicenter, double-blind, placebo-controlled, randomized phase III inMIND trial (NCT04680052).1 The Lymphoma Hub previously reported the primary results from this trial. Patients who received tafasitamab + rituximab + lenalidomide had a median progression-free survival of 22.4 months vs 13.9 months in the placebo + rituximab + lenalidomide arm (hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.32–0.58; p < 0.0001).1
Tafasitamab + rituximab + lenalidomide was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with R/R FL.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, does lisocabtagene maraleucel offer a durable, potentially curative remission with a one-time infusion in second-line large B-cell lymphoma?
